IBD-Associated Arthritis

Top Story

Anti-tumor Necrosis and Inflammatory Bowel Disease

Healio Rheumatology, June 2017
Edouard Louis, MD, PhD

A: The inflammatory bowel diseases are chronic, relapsing inflammatory disorders of the gastrointestinal tract with a propensity to develop tissue damage — including fibrosis and strictures — penetrating lesions and fistulas, and small bowel and colorectal cancer. Therefore, the aim of treatment is no longer a simple clinical response or even remission, but a state of biological and tissue remission ideally associated with the absence of disease progression. Any therapeutic decision in inflammatory bowel disease, either escalating or de-escalating the treatment, must be made by taking this into account.

Anti-tumor necrosis factors (TNFs), including infliximab, adalimumab and certolizumab pegol for Crohn’s disease (CD) and infliximab and adalimumab for ulcerative colitis (UC), have been used in clinical trials and routine practice for more than 10 years. These have been associated with long-term benefits, such as sustained clinical remission, mucosal healing, fistula healing, decreased number of hospitalizations, decreased number of surgeries, increased quality of life and the ability to work and perform activities of daily living. These have been associated with a reasonably good safety profile and, globally, a favorable benefit/risk ratio. The most striking risks are opportunistic infections, mainly tuberculosis (incidence of approximately one per 1,000 patients per year) and lymphomas (fewer than one per 1,000 treated patients).

In the Journals

Biosimilars unlikely to save costs as expected, experts say

May 4, 2017
Despite being heralded as lower-cost alternatives to branded biologics, the approval of biosimilar therapies for chronic diseases is not likely to yield expected cost…
Meeting NewsVideo

VIDEO: Speaker reviews factors that impact response to treatment for Crohn’s disease, ulcerative colitis

March 28, 2017
NEW YORK — At the Interdisciplinary Autoimmune Summit, Steven B. Hanauer, MD, medical director of the Digestive Health Center at Northwestern University, Feinberg…
Curbside Consultation

Biologic Therapies for Inflammatory Bowel Disease

Healio Rheumatology, March 2017
Maria Laura Annunziata, MD, PhD; David T. Rubin, MD
A: Current biologic therapies for inflammatory bowel disease include infliximab and adalimumab, which were approved in North America, Australia and Western Europe…
CME

Use of a Bipolar Blood-Sealing System During Total Joint Arthroplasty: December 2015

The goal of the clinical use of a bipolar blood-sealing system is to reduce perioperative blood loss in total joint…
More »
Video
Meeting News

VIDEO: Speaker reviews factors that impact response to treatment for Crohn’s disease, ulcerative colitis

March 28, 2017
More »
Featured
EULAR Annual Congress

EULAR Annual Congress

CME

Pediatric Rheumatology: June 2015

Keck School of Medicine of USC and Pediatric Annals

Of all the areas of pediatric practice, none can seem more daunting or require a higher index of suspicion than…
More »
Curbside Consultation

Anti-tumor Necrosis and Inflammatory Bowel Disease

Healio Rheumatology, June 2017
Edouard Louis, MD, PhD
A: The inflammatory bowel diseases are chronic, relapsing inflammatory disorders of the gastrointestinal tract with a propensity to develop tissue…

In the Journals

Biosimilars unlikely to save costs as expected, experts say

May 4, 2017
Despite being heralded as lower-cost alternatives to branded biologics, the approval of biosimilar therapies for chronic diseases is not likely to…

Meeting NewsVideo

VIDEO: Speaker reviews factors that impact response to treatment for Crohn’s disease, ulcerative colitis

March 28, 2017
NEW YORK — At the Interdisciplinary Autoimmune Summit, Steven B. Hanauer, MD, medical director of the Digestive Health Center

Curbside Consultation

Biologic Therapies for Inflammatory Bowel Disease

Healio Rheumatology, March 2017
Maria Laura Annunziata, MD, PhD; David T. Rubin, MD
A: Current biologic therapies for inflammatory bowel disease include infliximab and adalimumab, which were approved in North America, Australia and…

By the Book

Immunomodulators Azathioprine/6-Mercaptopurine and Methotrexate

Healio Rheumatology, February 2017
David T Rubin, MD; Miles P Sparrow, MBBS, FRACP
Treatment aims in the inflammatory bowel diseases are evolving beyond the induction and maintenance of corticosteroid-free remission. More recently…

FDA NewsPerspective

FDA issues draft guidance on biosimilar interchangeability

January 18, 2017
The FDA has released a draft guidance for industry outlining criteria for demonstrating that a biosimilar is interchangeable with a reference product…

By the Numbers

8 IBD updates from ACG, UEG Week

November 1, 2016
Several developments in inflammatory bowel disease were presented at the two major gastroenterology conferences last month: the American College of…

Meeting NewsPerspective

NOR-SWITCH: Switching to Remicade biosimilar safe, noninferior

October 24, 2016
Switching to biosimilar Remicade was safe and noninferior to continued treatment with the originator product across multiple indications, including…

Editorial

The Rising Tide of Autoimmunity: Highlights of the International Autoimmunity Summit

Healio Rheumatology, May 2016
Leonard H. Calabrese, DO
The International Autoimmunity Summit gathered several hundred experts who span the spectrum of autoimmune diseases, which are often referred to as…

By the Book

Extraintestinal Manifestations of IBD

Healio Rheumatology, April 2016
Ellen J. Scherl, MD
Extraintestinal manifestations of inflammatory bowel disease occur frequently. Disorders involving practically all organ systems have been reported…

More Headlines »
Advertisement
Advertisement